A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab

[1]  S. Polyzos,et al.  Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2‐Year Clinical Trial , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  A. Grauer,et al.  Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab , 2019, Osteoporosis International.

[3]  J. Cauley,et al.  Change in Bone Density and Reduction in Fracture Risk: A Meta‐Regression of Published Trials , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  D. Dempster,et al.  Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  A. Sudo,et al.  Efficacy of Switching From Teriparatide to Bisphosphonate or Denosumab: A Prospective, Randomized, Open‐Label Trial , 2018, JBMR plus.

[6]  Jacques P. Brown,et al.  Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double‐Blind, Phase 2, Parallel Group Study , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  A. Grauer,et al.  FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  R. Rizzoli,et al.  ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis , 2018, The Journal of clinical endocrinology and metabolism.

[9]  P. Geusens,et al.  Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial , 2017, The Lancet.

[10]  Jacques P. Brown,et al.  Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial , 2017, The Lancet.

[11]  A. Grauer,et al.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis , 2017, The New England journal of medicine.

[12]  I. Reid,et al.  Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial , 2017, Canadian Medical Association Journal.

[13]  M. McClung.  Using Osteoporosis Therapies in Combination , 2017, Current Osteoporosis Reports.

[14]  I. Reid,et al.  Bone Loss After Denosumab: Only Partial Protection with Zoledronate , 2017, Calcified Tissue International.

[15]  D. Dempster,et al.  Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  N. Watts,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[17]  A. Grauer,et al.  Romosozumab Treatment in Postmenopausal Women with Osteoporosis. , 2016, The New England journal of medicine.

[18]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[19]  N. Watts,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[20]  M. Stolina,et al.  Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats. , 2015, Bone.

[21]  Hang Lee,et al.  Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial , 2015, The Lancet.

[22]  O. Tørring,et al.  Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years , 2015, Osteoporosis International.

[23]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis International.

[24]  A. Kivitz,et al.  Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double‐blind, placebo‐controlled study , 2014, Journal of clinical pharmacology.

[25]  Ego Seeman,et al.  Differing effects of denosumab and alendronate on cortical and trabecular bone. , 2014, Bone.

[26]  Cesar Libanati,et al.  Romosozumab in postmenopausal women with low bone mineral density , 2014, The New England journal of medicine.

[27]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

[28]  S. Cummings,et al.  Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  N. Freemantle,et al.  Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women , 2011, Osteoporosis International.

[30]  E. Posvar,et al.  Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  C. Benhamou,et al.  Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass: A Randomized Controlled Trial , 2009, Obstetrics and gynecology.

[32]  S. Boonen,et al.  Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  H. Genant,et al.  Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  B. Stuckey,et al.  Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. , 2003, Archives of internal medicine.